Quick Takeaways
- Commodore Capital LP filed SCHEDULE 13G/A for Enliven Therapeutics, Inc. Common Stock, par value $0.001 per share (ELVN).
- Disclosed ownership: 9.9%.
- Date of event: 30 Jun 2025.
Commodore Capital LP - 30 Jun 2025 SCHEDULE 13G/A Report for Enliven Therapeutics, Inc. Common Stock, par value $0.001 per share (ELVN)
- Filing Manager
- Commodore Capital LP
- Reporting Manager
- Commodore Capital LP
- Symbol
- ELVN
- Shares outstanding
- 60,837,949 shares
- Disclosed Ownership
- 6,022,957 shares
- Ownership
- 9.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Aug 2025, 17:06:37 UTC
- Date of event
- 30 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Commodore Capital LP disclosed 9.9% ownership in Enliven Therapeutics, Inc. Common Stock, par value $0.001 per share (ELVN) on 30 Jun 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Aug 2025, 17:06.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 9.9% | 6,022,957 | 0 | 6,022,957 | Michael Kramarz | Managing Partner | |
| Commodore Capital Master LP | 9.9% | 6,022,957 | 0 | 6,022,957 | Michael Kramarz | Authoirzed Signatory | |
| Robert Egen Atkinson | 9.9% | 6,022,957 | 0 | 6,022,957 | Robert Egen Atkinson | Authoirzed Signatory | |
| Michael Kramarz | 9.9% | 6,022,957 | 0 | 6,022,957 | Michael Kramarz | Authoirzed Signatory |